

Target: ₹ 820 (16%) Target Period: 12 months

April 27, 2021

Healthy performance backed by fundamental strength

HDFC Life Insurance reported a steady performance led by healthy new business (led by diversified product mix) and renewal premium, steady persistency and investment income.

Gross premium growth remained healthy at 21.6% YoY to ₹ 12911 crore, led by steady traction in renewal to ₹ 6350 crore (up 14.9% YoY) and new business premium to ₹ 6560 crore (up 28.9% YoY). On an APE basis, growth in premiums increased 36.3% YoY to ₹ 2806 crore. Individual APE for FY21 was at ₹ 7120 crore, up 16% YoY. Growth in protection business remained slower with 4% YoY growth in individual premium to ₹ 480 crore while group premium declined 21% YoY to ₹ 3440 crore for FY21, primarily due to slowdown in credit disbursement. The company is seeing improving traction in business both in individual segment (term & par products) and group business (owing to revival in credit protect in Q4FY21). Partner tie-up in FY21 has started to witness business traction.

Commission ratio increased 50 bps YoY to 4.6% owing to increased business. Opex ratio (management expense) ratio remained steady YoY at 11.7%. Claims ratio increased YoY though healthy premium accretion led to surplus at ₹ 434 crore, up 219% YoY, 58% QoQ. PAT for the guarter was at ₹ 318 crore, flattish YoY, and lower than our estimate (due to higher contribution to policyholder's fund). AUM growth for the quarter was at ₹ 173839 crore, up 37% YoY owing to base effect. Persistency ratio largely remained buoyant with 13th month persistency at 90% and 61st month persistency at 53%.

New business margins continued to increase 60 bps QoQ to 27%, led by balanced product mix. Indian embedded value was at ₹ 26620 crore as of March 2021, up 18.5% YoY. Solvency ratio remained steady at 2.01x.

Valuation & Outlook

Product innovation and launches, diversified business mix and improving traction from recent tie-ups is seen keeping business momentum healthy. Focus on non-metro and non-salaried segment is expected to enhance customer base and thereby business traction. Revival in credit protect and focus on retirement products are seen aiding business growth and margins. We expect gross written premium (GWP) to grow at ~18% CAGR in FY21-23E to ₹ 53890 crore. Steady traction in individual term insurance and gradual pick up in credit protect is seen keeping VNB margin at ~25%. PAT is expected to grow at 10% CAGR over the same period to ₹ 1634 crore. HDFC Life currently trades at ~4.1x FY23E embedded value (EV), which is at a premium compared to its peers. Given the superior business franchise and continued focus on profitability, valuations are expected to remain at a premium. Considering the current business franchise and building anticipated improvement in business momentum and profitability metric, we maintain our target price of ₹ 820/share, valuing the company at ~4.7x FY23E EV. We maintain BUY recommendation on the stock.



BUY



| Particulars | |
|-----------------------|----------------|
| Particulars | Amount |
| Market Capitalisation | ₹ 142426 crore |
| EV (Q4FY21) | ₹ 26617 crore |
| AUM (Q4FY21) | ₹ 173839 crore |
| VNB margin (Q4FY21) | 27.0% |
| 52 week H/L | 746/ 451 |
| Net worth | ₹8428 crore |
| Face value | ₹ 10 |
| Dll holding (%) | 6.3 |
| Fll holding (%) | 25.7 |

Key Highlights

- Gross premium growth remained healthy at 21.6%
- Outstanding Covid provision at ₹ 165 crore
- Maintain BUY recommendation with unchanged target price of ₹ 820

Risk to our call

- Resurgence in Covid cases remains risk owing to probability of higher claims
- Interest rate volatility risk due to increased non-par business

Research Analyst

Kajal Gandhi kajal.gandhi@icicisecurities.com

Vishal Narnolia vishal.narnolia@icicisecurities.com

Sameer Sawant sameer.sawant@icicisecurities.com

| Key Financial Summary | | | | | | |
|-----------------------|-------|-------|-------|-------|-------|-----------------|
| (₹ Crore) | FY19 | FY20 | FY21 | FY22E | FY23E | CAGR (FY21-23E) |
| New business premium | 14971 | 17238 | 20107 | 24249 | 28401 | 19% |
| APE | 6049 | 7164 | 8183 | 10031 | 11662 | 19% |
| Total premium | 29186 | 32707 | 38584 | 45785 | 53890 | 18% |
| PAT | 1277 | 1295 | 1360 | 1588 | 1634 | 10% |
| EV | 18296 | 20655 | 26625 | 30930 | 35390 | 15% |
| P/E (x) | 111.4 | 109.9 | 104.6 | 89.7 | 87.2 | |
| P/BV (x) | 25.1 | 20.9 | 16.5 | 14.9 | 13.3 | |
| P/IEV (x) | 7.8 | 6.9 | 5.3 | 4.6 | 4.0 | |

Result Update

| Exhibit 1: Variance A | nalysis | | | | | | |
|-------------------------------|----------|----------|-----------|---------|----------|----------------|--|
| | Q4FY21 | Q4FY21E | Q4FY20 | YoY (%) | Q3FY21 | QoQ (%) | Comments |
| First Year Premium | 2,389.2 | 2,224.0 | 1,722.0 | 38.7 | 1,772.2 | 34.8 | |
| Renewal Premium | 6,350.4 | 6,233.4 | 5,526.2 | 14.9 | 4,577.0 | 38.7 | Stable persistency aids renewal premium growth |
| Single Premium | 4,170.6 | 4,266.9 | 3,366.7 | 23.9 | 3,279.0 | 27.2 | |
| Net Premium income | 12,868 | 12,471 | 10,464 | 23.0 | 9,487 | 35.6 | |
| Income from Investments | 6,323.3 | 4,001.6 | -10,045.8 | NA | 11,639.8 | -45.7 | |
| Total revenue | 19,191.3 | 16,472.3 | 418.6 | 4,484.2 | 21,126.8 | -9.2 | |
| Commission | 597.5 | 561.2 | 428.9 | 39.3 | 448.2 | 33.3 | Revival in business traction led to increase in comission |
| Operating expenses | 1,510.1 | 1,496.5 | 1,252.2 | 20.6 | 1,307.3 | 15.5 | |
| Management Expenses | 2,107.6 | 2,057.7 | 1,681.1 | 25.4 | 1,755.5 | 20.1 | |
| Benefits paid | 8,837.6 | 5,611.8 | 5,326.9 | 65.9 | 6,182.5 | 42.9 | ₹ 165 crore provided for covid reserve |
| Change in Actuarial Liability | 7,622.7 | 8,243.3 | -7,316.5 | -204.2 | 12,827.8 | -40.6 | |
| Total Expenses | 16,460.3 | 13,855.1 | -1,989.6 | -927.3 | 19,010.3 | -13.4 | |
| Surplus/ (deficit) | 617.8 | 369.5 | 258.2 | 139.2 | 315.5 | 95.8 | Higher premium accretion and investment income offset increase in claims |
| Transfer to SH's A/c | 286.6 | 325.0 | 451.7 | -36.5 | 139.8 | 105.1 | |
| Investment income | 271.3 | 164.2 | 104.6 | 159.4 | 142.7 | 90.1 | |
| Profit/ (loss) before tax | 309.1 | 393.6 | 284.5 | 8.7 | 267.0 | 15.8 | |
| РАТ | 317.9 | 391.6 | 311.7 | 2.0 | 265.0 | 20.0 | Higher allocation to policyholder led to lower than expected earnings |
| Key Metrics | | | | | | | |
| NBP | 6,559.8 | 6,490.9 | 5,088.7 | 28.9 | 5,051.2 | 29.9 | |
| AUM | 1,73,839 | 1,69,625 | 1,27,226 | 36.6 | 1,65,623 | 5.0 | Premium accretion and base effect led to YoY jump in AUN |

Source: Company, ICICI Direct Research


| Exhibit 2: Change in estimates | | | | | | | |
|-----------------------------------|--------|--------|----------|--------|--------|----------|--|
| | | FY22E | | | FY23E | | |
| (₹ Crore) | Old | New | % Change | Old | New | % Change | |
| Premiums earned - Net | 38,089 | 44,849 | 17.7 | 43,136 | 52,738 | 22.3 | |
| Total | 48,917 | 56,221 | 14.9 | 56,469 | 66,486 | 17.7 | |
| Transfer to Shareholders' account | 1,304 | 1,316 | 0.9 | 1,352 | 1,309 | -3.2 | |
| PAT | 1,577 | 1,588 | 0.7 | 1,676 | 1,634 | -2.5 | |
| EV/Share | 142 | 153 | 8.0 | 166 | 175 | 5.7 | |

Source: Company, ICICI Direct Research

| | | | Current | | Earlier | |
|--------------------|------|------|---------|-------|---------|-------|
| | FY20 | FY21 | FY22E | FY23E | FY22E | FY23E |
| NBP growth | 15.1 | 16.6 | 20.6 | 17.1 | 10.5 | 12.6 |
| AUM growth | 1.3 | 36.6 | -1.0 | 12.8 | 11.6 | 12.8 |
| EV Growth | 12.9 | 28.9 | 16.2 | 14.4 | 16.4 | 17.0 |
| Comission ratio | 4.6 | 4.4 | 4.3 | 4.3 | 4.3 | 4.3 |
| VNB Margin | 25.9 | 26.1 | 25.8 | 25.6 | 25.2 | 25.9 |
| Conservation ratio | 80.3 | 85.9 | 85.0 | 85.0 | 81.5 | 84.2 |


Story in Charts





Individual APE

Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research

Exhibit 7: GWP growth trajectory



Gross Written Premium

Source: Company, ICICI Direct Research

| Exhibit 9: Persistency ratios trend | | | | | | | | | | |
|-------------------------------------|--------|--------|--------|--------|--------|--------|--|--|--|--|
| Persisitency ratio % | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | Q3FY21 | Q4FY21 | | | | |
| 13th Month | 88.8 | 88.4 | 87 | 90.8 | 92.9 | 91.4 | | | | |
| 37th Month | 71.5 | 71.8 | 69.5 | 71.8 | 72.1 | 76.3 | | | | |
| 61th Month | 52.6 | 54.6 | 54.4 | 52.4 | 51.8 | 54.6 | | | | |

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

Exhibit 6: Improvement in persistency aids VNB margins



Source: Company, ICICI Direct Research

Exhibit 8: Increasing PH surplus









Exhibit 11: Healthy return on EV%




Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

| Exhibit 12: Shareholding Pattern | | | | | | | | | |
|----------------------------------|--------|--------|--------|--------|---------|--|--|--|--|
| | Mar-20 | Jun-20 | Sep-20 | Dec-20 | Mar- 21 | | | | |
| Promoter | 63.7 | 60.4 | 60.4 | 58.9 | 58.9 | | | | |
| FII | 21.1 | 23.6 | 23.4 | 24.9 | 25.7 | | | | |
| Others | 9.2 | 8.8 | 8.9 | 9.2 | 9.2 | | | | |

Source: Company, ICICI Direct Research

Exhibit 13: Price Performance



Source: Company, ICICI Direct Research

ICICI Direct Research

Financial summary

| (₹ Crore) | FY19 | FY20 | FY21 | FY22E | FY23E |
|---|---------|---------|---------|---------|---------|
| Premiums earned - Net | 28924.0 | 32223.6 | 38122.3 | 44848.6 | 52737.8 |
| Interest, Dividends & Rent | 9027.5 | 6845.3 | 32677.6 | 10720.5 | 12977.4 |
| Others income (incl. MTM) | 484.0 | -9807.5 | 442.0 | 651.9 | 770.3 |
| Total Revenue | 38,436 | 29,261 | 71,242 | 56,221 | 66,486 |
| Commission | 1117.7 | 1491.18 | 1710.40 | 1960.3 | 2302.5 |
| Operating expenses | 3813.6 | 4266.9 | 4587.4 | 6123.0 | 7200.7 |
| Change in valuation of policy liabilities | 17507.5 | 2440.8 | 40829.6 | 23192.4 | 28276.2 |
| Provision for tax | 226.8 | 149.0 | 274.4 | 233.6 | 307.6 |
| Surplus/(deficit) after tax | 1350.7 | 971.4 | 1098.4 | 1324.0 | 1508.1 |
| Transfer to Shareholders' account | 1,207 | 1,191 | 991 | 1,316 | 1,309 |

Source: Company, ICICI Direct Research

| Exhibit 15: Shareholders Account | | | | | |
|---|--------|--------|--------|--------|--------|
| (₹ Crore) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Amounts transferred from Policyholders' account | 1206.9 | 1191.4 | 990.9 | 1315.6 | 1308.9 |
| Income from investments | 408.4 | 437.8 | 647.6 | 651.8 | 711.1 |
| Total | 1,636 | 1,648 | 1,638 | 1,967 | 2,020 |
| Total expenses | 62.6 | 99.1 | 285.0 | 346.5 | 336.0 |
| Profit before Tax | 1289.9 | 1311.7 | 1353.5 | 1637.5 | 1685.0 |
| Provision for tax | 13.1 | 16.5 | -6.6 | 49.1 | 50.6 |
| PAT | 1,277 | 1,295 | 1,360 | 1,588 | 1,634 |

Source: Company, ICICI Direct Research

| Exhibit 16: Balance Sheet | | | | | |
|--|--------|--------|--------|--------|--------|
| (₹ Crore) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Sources of Funds | | | | | |
| Share capital | 2017 | 2019 | 2021 | 2021 | 2021 |
| Reserve and surplus | 3641 | 4968 | 6407 | 7342 | 8485 |
| Credit/[debit] fair value change account | -3 | -192 | 207 | 215 | 224 |
| Networth | 5656 | 6800 | 8638 | 9579 | 10730 |
| Policyholders' funds | 118124 | 119502 | 162818 | 177508 | 206359 |
| Funds for Future Appropriations | 1103 | 883 | 991 | 999 | 1198 |
| Total Liabilities | 124883 | 127185 | 173066 | 188086 | 218287 |
| Applications of Funds | | | | | |
| Shareholders' investments | 5050 | 5855 | 8542 | 7407 | 8889 |
| Policyholders' investments | 57124 | 67189 | 90538 | 93584 | 107685 |
| Asset held to cover linked liabilities | 63377 | 54182 | 74760 | 71114 | 77514 |
| Loans | 80 | 299 | 424 | 60 | 60 |
| Fixed assets - net block | 333 | 330 | 340 | 347 | 354 |
| Net current assets | -1082 | -670 | -1538 | 15574 | 23785 |
| Total Assets | 124883 | 127185 | 173066 | 188086 | 218287 |

| (Year-end March) | FY19 | FY20 | FY21 | FY22E | FY23E |
|--|-------|-------|-------|-------|-------|
| Valuation | | | | | |
| No. of Equity Shares (Crore) | 201.7 | 201.9 | 201.9 | 202.1 | 202.1 |
| Diluted EPS (₹) | 6.3 | 6.4 | 6.7 | 7.9 | 8.1 |
| BV (₹) | 28.0 | 33.7 | 42.8 | 47.4 | 53.1 |
| EV per share | 90.7 | 102.3 | 131.9 | 153.0 | 175.1 |
| P/E | 111.4 | 109.9 | 104.6 | 89.7 | 87.2 |
| P/BV | 25.1 | 20.9 | 16.5 | 14.9 | 13.3 |
| P/IEV | 7.8 | 6.9 | 5.3 | 4.6 | 4.0 |
| Efficiency Ratios (%) | | | | | |
| Commission expenses as a % of Gross Premium | 3.8 | 4.6 | 4.4 | 4.3 | 4.3 |
| Management expenses incl commission as a % of Gross Premium | 16.9 | 17.6 | 16.3 | 17.7 | 17.6 |
| Return Ratios and capital (%) | | | | | |
| Return on Net worth | 24.5 | 20.8 | 17.6 | 18.0 | 18.1 |
| Opearating RoEV | 20.1 | 18.1 | 18.5 | 18.4 | 18.5 |
| Key Ratios (%) | | | | | |
| VNB Margin | 24.6 | 25.9 | 26.1 | 25.8 | 25.6 |
| NBP APE (proportion %) | | | | | |
| Paticipating | 14.4% | 15.9% | 14.6% | 16.7% | 17.3% |
| Non participating | 38.5% | 59.5% | 53.5% | 59.5% | 59.2% |
| Unit Linked | 47.1% | 24.5% | 21.7% | 23.8% | 23.5% |

| Exhibit 18: Key par | Exhibit 18: Key parameters | | | | | | | | | | | |
|---------------------|----------------------------|----------|----------|----------|----------|--|--|--|--|--|--|--|
| (Year-end March) | FY19 | FY20 | FY21 | FY22E | FY23E | | | | | | | |
| NBP | 14,971 | 17,238 | 20,107 | 24,249 | 28,401 | | | | | | | |
| Growth (%) | 31.9 | 15.1 | 16.6 | 20.6 | 17.1 | | | | | | | |
| Linked | 11,322 | 11,192 | 11,055 | 12,593 | 13,713 | | | | | | | |
| Growth (%) | 10.3 | -1.1 | -1.2 | 13.9 | 8.9 | | | | | | | |
| Non Linked | 17,864 | 21,514 | 24,281 | 33,192 | 40,177 | | | | | | | |
| Growth (%) | 34.4 | 20.4 | 12.9 | 36.7 | 21.0 | | | | | | | |
| APE | 6,049 | 7,164 | 8,183 | 10,031 | 11,662 | | | | | | | |
| Growth (%) | 12.0 | 18.4 | 14.2 | 22.6 | 16.3 | | | | | | | |
| VNB | 1,540 | 1,919 | 2,190 | 2,648 | 3,054 | | | | | | | |
| Growth (%) | 20.1 | 24.6 | 14.1 | 20.9 | 15.4 | | | | | | | |
| EV | 18,296 | 20,655 | 26,625 | 30,930 | 35,390 | | | | | | | |
| Growth (%) | 20.2 | 12.9 | 28.9 | 16.2 | 14.4 | | | | | | | |
| AUM | 1,25,552 | 1,27,226 | 1,73,839 | 1,72,105 | 1,94,088 | | | | | | | |
| Growth (%) | 17.8 | 1.3 | 36.6 | -1.0 | 12.8 | | | | | | | |
| PH Funds | 57,124 | 67,189 | 90,538 | 93,584 | 1,07,685 | | | | | | | |
| Growth (%) | 26.0 | 17.6 | 34.8 | 3.4 | 15.1 | | | | | | | |
| SH Funds | 5,050 | 5,855 | 8,542 | 7,407 | 8,889 | | | | | | | |

Source: Company, ICICI Direct Research

| Exhibit 19: ICICI Direct coverage universe (Insurance) | | | | | | | | | | | | | | | | | | | |
|--|-----|-------|--------|---------------|------|-------|---------|-------|-------|----------|------|-------|-----------|------|-------|----------------|------|-------|-------|
| Sector / Company | CMP | | | M Cap EPS (₹) | | S (₹) | P/E (x) | | | P/EV (x) | | | RoAUM (%) | | | RoE (%) | | | |
| | (₹) | TP(₹) | Rating | (₹ bn) | FY21 | FY22E | FY23E | FY21 | FY22E | FY23E | FY21 | FY22E | FY23E | FY21 | FY22E | FY23E | FY21 | FY22E | FY23E |
| SBI Life Insurance | 930 | 1000 | Buy | 929 | 15.8 | 19.5 | 23.4 | 59.0 | 47.7 | 39.7 | 3.1 | 2.7 | 2.4 | 0.8 | 0.9 | 0.9 | 15.2 | 14.6 | 14.3 |
| HDFC Life | 705 | 820 | Buy | 1424 | 6.7 | 7.9 | 8.1 | 104.6 | 89.7 | 87.2 | 5.3 | 4.6 | 4.0 | 0.9 | 0.9 | 0.8 | 17.6 | 17.4 | 16.1 |

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Kajal Gandhi, CA, Vishal Narnolia, MBA and Sameer Sawant, MBA Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.